Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 21, 2023
Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trialPhilippe Merle, Jean-Frédéric Blanc, Julien Edeline, et al.
Frontiers in Oncology|October 11, 2021
Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case ReportRomain Varnier, Thibaut Garrivier, Emilie Hafliger, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2022
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD studyCôme Lepage, Jean-Marc Phelip, Astrid Lievre, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2018
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trialsThomas Aparicio, Michel Ducreux, Roger Faroux, et al.
British Journal of Cancer|February 5, 2020
Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trialThomas Aparicio, Jaafar Bennouna, Karine Le Malicot, et al.
Frontiers in Oncology|November 28, 2022
Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancerAdrien Grancher, Ludivine Beaussire, Sylvain Manfredi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 30, 2022
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trialClélia Coutzac, Frederic Bibeau, Meher Ben Abdelghani, et al.
The Lancet. Gastroenterology & Hepatology|June 22, 2026
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trialPhilippe Merle, Jean-Frederic Blanc, Karine Le Malicot, et al.
British Journal of Cancer|May 30, 2018
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH studyIan Chau, Joon Oh Park, Baek-Yeol Ryoo, et al.
Journal of Hepatology|May 25, 2019
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinomaJean-Louis Jouve, Thierry Lecomte, Olivier Bouché, et al.
Pageof 10